154566-12-8
154566-12-8 结构式
基本信息
SB-204990(消旋)
SB-204990(racemic)
YTRNLFYTHYWDAU-KDOFPFPSSA-N
SB204990,Inhibitor,inhibit,ACLY,SB 204990,ATP Citrate Lyase,SB-204990
(3R,5S)-rel-5-[6-(2,4-Dichlorophenyl)hexyl]tetrahydro-3-hydroxy-2-oxo-3-furanacetic acid
2-((3R,5S)-5-(6-(2,4-dichlorophenyl)hexyl)-3-hydroxy-2-oxotetrahydrofuran-3-yl)acetic acid
3-Furanacetic acid, 5-[6-(2,4-dichlorophenyl)hexyl]tetrahydro-3-hydroxy-2-oxo-, (3R,5S)-rel-
物理化学性质
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2024/04/30 | HY-16450 | 化合物SB 204990 SB 204990 | 154566-12-8 | 10mM * 1mLin DMSO | 1320元 |
| 2024/04/30 | HY-16450 | 化合物SB 204990 SB 204990 | 154566-12-8 | 10mg | 2040元 |
| 2024/04/30 | HY-16450 | 化合物SB 204990 SB 204990 | 154566-12-8 | 50mg | 7700元 |
常见问题列表
ACLY.
SB204990 (SB) is a specific inhibitor of ACLY enzyme. SB204990 treatment leads to a decrease in cytosolic Ac-CoA level and is thus expected to decrease acetylated and active β-catenin levels.
SB 204990, when administered orally to rats, is absorbed into the systemic circulation. When administered in the diet (0.05-0.25%, w/w) for 1 week, SB 204990 causes a dose-related decrease in plasma cholesterol (by up to 46%) and triglyceride levels (by up to 80%) in rats. SB 204990 (25 mg/kg per day) also decreases plasma cholesterol levels (by up to 23%) and triglyceride levels (by up to 38%) in the dog, preferentially decreasing low-density lipoprotein compared with high-density lipoprotein cholesterol levels.